Induction of Immune Responses by Recombinant PH-1 Domain of Infectious Laryngotracheitis Virus Glycoprotein B in Chickens

Shahsavandi, Shahla; Ebrahimi, Mohammad Majid; Faramarzi, Samireh

doi:10.1089/vim.2021.0024

Cited by 1 publication

(1 citation statement)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This high level of antibody titer may be attributed to the high dose of DNA vaccine used for immunization (20g/dose in two doses) that span the replication advantage of the live TC ILT vaccine used. the ability of gpB DNA vaccine to induce such powerful humoral immune response was reported earlier [32,33] . Bioinformatics' analysis of gpB of ILT virus revealed the presence of more than 30 unique linear epitopes based on B-lymphocytes binding affinity [13,34 ],So DNA vaccines exhibit many advantages [10], such as long persistence of immunogenicity and induction of a wide range of both humoral and cell-mediated immunity [30], and lack of the risk of infection (in contrast to the live tissue culture or egg propagated ILT vaccines which have an issue in the presence of residual virulence, which might be exacerbated with the passage in the chicken farms after vaccinal application [24] and the revertants to the virulent state that attributes to later outbreaks…”

Section: Discussionmentioning

confidence: 59%

Humoral and Interferon-γ Immune Response to DNA Vaccine Encoding The surface Glycoprotein B of Infectious Laryngotracheitis Virus

Gamal

Soliman

2023

Egyptian Journal of Veterinary Sciences

View full text Add to dashboard Cite

D NA vaccines continue to be a suitable safe and potent alternative particularly for controlling the infection with pathogens that rely on the cell-mediated type of immune response and for the ability to eliminate viral shedding Infectious laryngotracheitis virus causes a contagious respiratory disease with a considerable economic impact. The aim of current study was developing of a DNA vaccine coding for the surface glycoprotein B gene (gpB) from locally isolated strain. The developed vaccine (pcDEST40-gpB) could elicit potent antibody titers positively correlated with the commercially available live TC-propagated ILT vaccine. IFN-γ gene transcript revealed that both DNA vaccine and live vaccine initiate a powerful fold change in IFN-γ till the 15 days post-vaccination, however, by day 7 post-challenge, the use of a booster dose of DNA vaccine resulted in an abrupt increase in the level of IFN-γ gene transcript, which was significantly higher than that of the live vaccine. Surprisingly, the data present here revealed that the DNA vaccine, but not the live vaccine, could prevent virus shedding after a challenge.

show abstract